银杏达莫联合依达拉奉治疗急性脑梗死的临床疗效观察

摘要

Objective To observe the clinical effect of yinxingdamo combined with edaravone on acute cerebral infarction. Methods A total of 128 patients with acute cerebral infarction were selected in the People′s Hospital of Baise from January 2013 to January 2015,and they were divided into control group(n = 56)and treatment group(n = 72)according to Medical Research Random Grouping Systems RandA 1. 0 and the will of patients or their family member. Patients of control group received conventional treatment after admission,while patients of treatment group received yinxingdamo combined with edaravone based on conventional treatment;both groups continuously treated for 14 days. Infarct volume,plasma Hcy level and NIHSS score were compared between the two groups at admission and after 15 days of admission,survival situation was recorded after 15 days of admission;patients of both groups were followed up for 6 months to evaluate the improvement effect of activities of daily living. Results No statistically significant differences of infarct volume,plasma Hcy level or NIHSS score was found between the two groups at admission( P ﹥ 0. 05);after 15 days of admission,infarct volume of treatment group was statistically significantly smaller than that of control group,plasma Hcy level and NIHSS score of treatment group were statistically significantly lower than those of control group(P < 0. 05). After 15 days of admission,the survival rate of treatment group was 80. 5% ,that of control group was 64. 3% ,the survival curve was statistically significantly different between the two groups( P < 0. 05 ). The improvement effect of activities of daily living of treatment group was statistically significantly better than that of control group at the end of follow - up(P < 0. 05). Conclusion Yinxingdamo combined with edaravone has certain clinical effect in treating acute cerebral infarction,can effectively improve the neurological function,activities of daily living and prognosis,reduce the risk of death.%目的：观察银杏达莫联合依达拉奉治疗急性脑梗死（ACI）的临床疗效。方法选取百色市人民医院2013年1月—2015年1月收治的 ACI 患者128例，应用医学研究随机分组系统 RandA 1.0并结合患者或其家属意愿分为治疗组72例和对照组56例。对照组患者给予常规治疗，治疗组患者在常规治疗基础上给予银杏达莫联合依达拉奉治疗，两组患者均治疗14 d。比较两组患者入院即刻和入院15 d 梗死体积、血浆同型半胱氨酸（Hcy）水平、美国国立卫生研究院卒中量表（NIHSS）评分，统计两组患者入院15 d 生存情况；两组患者均随访6个月，并于随访结束时评定患者日常生活活动能力改善效果。结果入院即刻两组患者梗死体积、血浆 Hcy 水平及 NIHSS 评分比较，差异无统计学意义（P ﹥0.05）；入院15 d 治疗组患者梗死体积小于治疗组，血浆 Hcy 水平和 NIHSS 评分均低于对照组（P ＜0.05）。入院15d，治疗组与对照组患者生存率分别为80.5%、64.3%，两组患者生存曲线比较，差异有统计学意义（P ＜0.05）。随访结束后治疗组患者日常生活活动能力改善效果优于对照组（P ＜0.05）。结论银杏达莫联合依达拉奉治疗 ACI 的临床疗效确切，能有效改善患者神经功能、日常生活活动能力及预后，降低患者死亡风险。